STONY BROOK, N.Y. – March 29, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was […]
The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines.
– Planned Doubling of Current DNA Production Capacity will Enable Company to Support Customers from Early-stage Drug Discovery Through Late-phase Clinical Trials – – Expansion Plans Catalyzed by Growing Industry Demand for LinearDNA™, Repeat and New Proof-of-Concept Orders from Customers with Long-Term Requirements for cGMP DNA – Operational Commencement Expected in 2H CY2023 – STONY […]
STONY BROOK, N.Y. – October 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a […]
Promising Results Support Further Development of LinearDNA as a Next Generation Vaccine Platform STONY BROOK, N.Y. – September 26, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (PCR”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing […]
– Agreement Leverages Company’s Ability for Intramuscular Delivery of LNP-Encapsulated LinearDNA-based Therapies for Veterinary Therapeutic and Prophylactic Applications – STONY BROOK, N.Y. and ITHICA, N.Y. – September 8, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, and the Cornell University College of […]
– Use of LNP Simplifies Administration of LinearDNA-based Therapies, Potentially Enabling Their Application in Large Scale – STONY BROOK, N.Y. – August 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that LineaRx, the Company’s majority-owned biotherapeutics subsidiary, has for the first time […]
Proprietary, highly efficient and scalable linDNA (linear DNA, the product of PCR) manufacturing process for use in nucleic acid-based therapies. Learn how LineaRx is the common denominator of next-generation therapies.
– Separately, LineaRx Announces Successful Expression In Vitro of Vaccine Candidate Encapsulated with Lipid Nanoparticles – STONY BROOK, N.Y. July 25, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular […]
– Industry Leaders Will Learn How LinearDNA Can Significantly Improve RNA Manufacturing Speed, Simplicity, and Scalability in Comparison to Plasmid DNA – STONY BROOK, N.Y. – July 22, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied […]